Video Insights
Advertisement
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
Dr. Hope evaluates PSMA PET vs SPECT imaging for tracking therapy response in prostate cancer.
Dr. Hofman outlines promising PSMA combination therapies and emerging trials aiming to improve prostate cancer outcomes.
Dr. Tyson discusses real-world decision-making around bladder-sparing options for BCG-unresponsive NMIBC.
Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.
Drs. Beckermann and Braun reflect on key lessons from the trial, emphasizing the importance of prioritizing driver mutations.
Drs. Beckermann and Braun break down the selection process for neoantigens in the trial for personalized RCC vaccines.
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...
Using Decipher in the SPPORT Study: Determining Response to Randomized Post-Prostatectomy Salvage RT
Dr. Tran discusses the benefits of the Decipher score as well as how stratified patients respond differently.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
Dr. Ciuro discusses key factors to consider when choosing between doublet and triplet therapy for mHSPC.
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Dr. Sonpavde showcases a phase I/Ib clincial trial on the safety of a neoadjuvant darolutamide and relugolix combination.
Dr. Sonpavde provides an overview of a phase I/II trial in progress on V940 (mRNA-4157) for resected high-risk MIUC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.